• Home
  •  / Acticor Biotech

Acticor Biotech

OverviewSuggest Edit

Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke. The Company develops a biologic drug candidate based on academic research on a platelet glycoprotein called GPVI.

TypePrivate
Founded2013
HQParis, FRMap
Websiteacticor-biotech.com

Recent NewsAll News

Latest Updates

Employees (est.) (Apr 2021)23(-4%)
Cybersecurity ratingBMore

Key People/Management at Acticor Biotech

Gilles Avenard

Gilles Avenard

Chief Executive Officer - Chairman of the Board
Andrea Comenducci

Andrea Comenducci

Medical Director
Catherine Boule

Catherine Boule

Director
Eric Cohen

Eric Cohen

Chief Financial Officer
Jean-Pierre Cazenave

Jean-Pierre Cazenave

Independent Director
Leila Nicolas

Leila Nicolas

Director
Show more

Acticor Biotech Office Locations

Acticor Biotech has an office in Paris
Paris, FR (HQ)
46 Rue Henri Huchard
Paris, FR
27 Rue du Faubourg Saint-Jacques
Show all (2)

Acticor Biotech Financials and Metrics

Summary Metrics

Founding Date

2013

Acticor Biotech total Funding

$33.3 m

Acticor Biotech latest funding size

$7.75 m

Time since last funding

a year ago

Acticor Biotech investors

Go Capital, CapDecisif Management, Anaxago, ARMESA, Primer Capital, CapDicisif Management, Mirae Asset Financial Group, Newton Biocapital, CMS Midical Venture Investment, A&B (HK)
Acticor Biotech's latest funding round in November 2019 was reported to be $7.8 m. In total, Acticor Biotech has raised $33.3 m
Show all financial metrics

Acticor Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

Learn more about our premium products
SecurityScorecard logo

Acticor Biotech Online and Social Media Presence

Acticor Biotech's Trends

Embed Graph

Acticor Biotech Blogs

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

– Approval of phase 2 GARDEN study in France and Brazil – GARDEN will enroll 60 patients hospitalized for COVID19 – First Patient included at University Hospital of Strasbourg Paris, December 22th, 2020 ​– Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombo…
October 01, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Paris, October 1st, 2020 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients w…
June 09, 2020

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

In The Journal of Clinical Pharmacology 2020, 00(0) 1–11 Authors Lionel Renaud, MSc , Kristell Lebozec, MSc, Christine Voors-Pette, MD, Peter Dogterom, PhD, Philippe Billiald, PharmD, Martine Jandrot Perrus, MD, Yannick Pletan, MD, and Matthias Machacek, PhD Abstract Glenzocimab (ACT017) is a humani…
January 27, 2020

Interview de Franck Mouthon, Président de France Biotech, sur les sociétés de santé ayant intégré la French Tech 120 sur BFM Business.

Franck Mouthon (France Biotech) : Le French Tech 120 compte 20 sociétés Health Tech
January 21, 2020

ACTICOR BIOTECH ENTERS THE 1ST FRENCH TECH 120

A NATIONAL PROGRAM TO PROMOTE AND SUPPORT FUTURE TECHNOLOGICAL LEADERS IN THEIR INTERNATIONAL DEVELOPMENT. Paris, January 21th, 2020 – ACTICOR Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced that it …
January 16, 2020

Meet us at Biotech Showcase (San Fransisco, CA, Jan. 13-15 202)

Come and meet Sophie LEBEL-BINAY (COO, CSO) and Eric COHEN (CFO) at Biotech Showcase in San Fransisco from Jan. 13 to Jan 15., 2020
Show more

 Acticor Biotech Frequently Asked Questions

  • When was Acticor Biotech founded?

    Acticor Biotech was founded in 2013.

  • Who are Acticor Biotech key executives?

    Acticor Biotech's key executives are Gilles Avenard, Andrea Comenducci and Catherine Boule.

  • How many employees does Acticor Biotech have?

    Acticor Biotech has 23 employees.

  • Who are Acticor Biotech competitors?

    Competitors of Acticor Biotech include Ortho Dermatologics, Bath ASU and Antibe Therapeutics.

  • Where is Acticor Biotech headquarters?

    Acticor Biotech headquarters is located at 46 Rue Henri Huchard, Paris.

  • Where are Acticor Biotech offices?

    Acticor Biotech has an office in Paris.

  • How many offices does Acticor Biotech have?

    Acticor Biotech has 2 offices.